Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Net Cash Flow (2018 - 2025)

10x Genomics (TXG) has disclosed Net Cash Flow for 8 consecutive years, with $41.2 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 176.57% to $41.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129.4 million through Dec 2025, up 959.73% year-over-year, with the annual reading at $129.4 million for FY2025, 959.73% up from the prior year.
  • Net Cash Flow hit $41.2 million in Q4 2025 for 10x Genomics, up from $35.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $112.4 million in Q1 2023 to a low of -$275.9 million in Q1 2022.
  • Historically, Net Cash Flow has averaged -$10.8 million across 5 years, with a median of -$6.2 million in 2023.
  • Biggest five-year swings in Net Cash Flow: crashed 903.58% in 2022 and later soared 1051.66% in 2025.
  • Year by year, Net Cash Flow stood at -$12.9 million in 2021, then decreased by 11.91% to -$14.4 million in 2022, then soared by 407.79% to $44.5 million in 2023, then crashed by 221.03% to -$53.8 million in 2024, then skyrocketed by 176.57% to $41.2 million in 2025.
  • Business Quant data shows Net Cash Flow for TXG at $41.2 million in Q4 2025, $35.0 million in Q3 2025, and $20.3 million in Q2 2025.